Cadrenal Therapeutics, Inc.(CVKD)
$1.72-0.16 (-8.51%)
CVKD
Cadrenal Therapeutics, Inc. financials statements
$1.72
At close:-0.16 (-8.51%)
Want to see CVKD full AI Analyst Report?
Cadrenal Therapeutics, Inc. (CVKD) Ratios
450 Followers
Cadrenal Therapeutics, Inc. Ratios
CVKD's free cash flow for Q2 2026 was $-2.23M. For the 2026 fiscal year, CVKD's free cash flow was increased by $0.00 and operating cash flow was $-2.23M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Quick Ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Cash Ratio | 2.52 | 3.73 | 10.16 | 0.02 |
| Solvency Ratio | -8.33 | -3.97 | -10.10 | -1.06 |
| Operating Cash Flow Ratio | -7.94 | -2.74 | -4.27 | -0.90 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -27.55 |
| Net Current Asset Value | $ 2.73M | $ 7.43M | $ 7.67M | $ -5.60M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.82 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | -0.12 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.11 |
| Financial Leverage Ratio | 1.58 | 1.36 | 1.11 | -0.14 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -487.57 | -43.80 |
| Interest Coverage Ratio | 0.00 | 0.00 | -446.34 | -25.22 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.04 | 0.96 |
| Net Debt to EBITDA | 0.30 | 0.94 | 1.01 | -0.09 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.34% | 97.18% | 109.49% | 248.53% |
| Return on Assets (ROA) | -305.95% | -105.21% | -98.10% | -862.83% |
| Return on Equity (ROE) | -483.34% | -143.17% | -108.64% | 120.95% |
| Return on Capital Employed (ROCE) | -491.51% | -147.33% | -99.23% | 485.64% |
| Return on Invested Capital (ROIC) | -491.51% | -147.33% | -98.95% | 551.03% |
| Return on Tangible Assets | -305.95% | -105.21% | -98.10% | -862.83% |
| Earnings Yield | -97.93% | -60.28% | -86.72% | -14.01% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -116735.71 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 116735.71 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -6.32 | -6.03 | -4.07 | -1.55 |
| Free Cash Flow Per Share | -6.32 | -6.04 | -4.07 | -1.55 |
| Dividend Paid and CapEx Coverage Ratio | -2468.98 | -1125.52 | -1084.92 | 0.00 |
| Capital Expenditure Coverage Ratio | -2468.98 | -1125.52 | -1084.92 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -165.35 | -1.88 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -93.22% | -41.67% | -36.67% | -2.51% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -1.02 | -1.66 | -1.15 | -7.14 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.94 | 2.38 | 1.25 | -8.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.07 | -2.40 | -2.73 | -39.79 |
| Price-to-Operating Cash Flow Ratio | -1.07 | -2.40 | -2.73 | -39.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.18 | -0.10 | 0.00 |
| Enterprise Value Multiple | -0.72 | -0.72 | -0.15 | -7.35 |
| Enterprise Value | 9.51M | 7.65M | 1.26M | 48.54M |
| EV to EBITDA | -0.72 | -0.72 | -0.15 | -7.35 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.75 | -1.04 | -0.36 | -40.29 |
| EV to Operating Cash Flow | -0.75 | -1.04 | -0.36 | -40.29 |
| Tangible Book Value Per Share | 1.37 | 6.10 | 8.86 | -7.16 |
| Shareholders’ Equity Per Share | 1.37 | 6.10 | 8.86 | -7.16 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -6.64 | -8.73 | -9.63 | -8.66 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.02 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.95 | 0.69 | 0.42 | 0.18 |
Currency in USD

